Do we need MRI in all biopsy naïve patients? A multicenter cohort analysis

1

MRI improves detection of clinically significant prostate cancer (csPCA) and reduces overdiagnosis of clinically non-significant prostate cancer (nsPCA).
2

MRI-targeted biopsy (TB) has limitations, including technical issues and variability in interpretation, affecting its reliability in detecting csPCA.
3

Systematic biopsy (SB) remains essential for biopsy-naïve men, as MRI's negative predictive value does not justify skipping biopsy based on MRI results alone.
4

Combined biopsy (CB) outperforms both TB and SB in cancer detection rates, particularly for csPCA, highlighting the need for comprehensive assessment.
5

Barriers such as access, costs, and provider training hinder the widespread adoption of advanced biopsy techniques despite their benefits.

World Journal Of Urology

by Philipp Krausewitz, Angelika Borkowetz, Gernot Ortner, Kira Kornienko, Mike Wenzel, Niklas Westhoff
February 7, 2024

1